Federica Grillo

Prof. Federica Grillo

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Pathologica
Verified
Journal Article
Open access
PDF file
IGIrene Gullo
Irene Gullo
FGFederica Grillo
Federica Grillo
LMLuca Mastracci
Luca Mastracci
AVAlessandro Vanoli
Alessandro Vanoli
FCFátima Carneiro
Fátima Carneiro
Matteo FassanMatteo Fassan
Matteo Fassan
Gastric cancer accounts for about 6% of cancers worldwide, being the fifth most frequently diagnosed malignancy and the third leading cause of cancer related death. Gastric carcinogenesis is a multistep and multifactorial process and is the result of the complex interplay between genetic susceptibility and environmental factors. The identification of predisposing conditions and of precancerous lesions is the basis for screening programs and early stage treatment. Furthermore, although most gastric cancers are sporadic, familial clustering is observed in up to 10% of patients. Among them, hereditary cases, related to known cancer susceptibility syndromes and/or genetic causes are thought to account for 1-3% of all gastric cancers. The pathology report of gastric resections specimens therefore requires a standardized approach as well as in depth knowledge of prognostic and treatment associated factors.

1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
SSSamantha Sarcognato
Samantha Sarcognato
DSDiana Sacchi
Diana Sacchi
FGFederica Grillo
Federica Grillo
NCNora Cazzagon
Nora Cazzagon
LFLuca Fabris
Luca Fabris
MGMaria Guido
Maria Guido
Autoimmune cholestatic liver diseases are rare hepato-biliary disorders characterized by a progressive, inflammatory destruction of bile ducts. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the main autoimmune cholestatic liver diseases. Both may evolve into secondary biliary cirrhosis and its complications. Therapeutic options are limited and liver transplantation remains the only definitive treatment for PBC and PSC. Most PBC and PSC patients have a typical presentation, which does not require liver biopsy. However, in routine clinical practice, important variants or specific subgroups that benefit from liver biopsy for proper management may be observed. Herein, we provide a general overview of clinical and pathological characteristic of PBC and PSC, highlighting the most important features for routine diagnostic practice.

11 March 2015 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
FGFederica Grillo
Federica Grillo
SPSimona Pigozzi
Simona Pigozzi
PCPaola Ceriolo
Paola Ceriolo
PCPaola Calamaro
Paola Calamaro
RFRoberto Fiocca
Roberto Fiocca
LMLuca Mastracci
Luca Mastracci

1 April 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FGFederica Grillo
Federica Grillo
EBEmanuela Barisione
Emanuela Barisione
LBLorenzo Ball
Lorenzo Ball
LMLuca Mastracci
Luca Mastracci
RFRoberto Fiocca
Roberto Fiocca

23 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Andrea remoAndrea remo
Andrea remo
Matteo FassanMatteo Fassan
Matteo Fassan
AVAlessandro Vanoli
Alessandro Vanoli
LBLuca Reggiani Bonetti
Luca Reggiani Bonetti
Valeria BarresiValeria Barresi
Valeria Barresi
LMLuca Mastracci
Luca Mastracci
Several histopathological variants of colorectal carcinoma can be distinguished, some associated with specific molecular profiles. However, in routine practice, ninety/ninety-five percent of all large bowel tumors are diagnosed as conventional adenocarcinoma, even though they are a heterogeneous group including rare histotypes, which are often under-recognized. Indeed, colorectal cancer exhibits differences in incidence, location of tumor, pathogenesis, molecular pathways and outcome depending on histotype. The aim is therefore to review the morphological and molecular features of these rare variants of intestinal carcinomas which may hold the key to differences in prognosis and treatment.

1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
CCClaudia Covelli
Claudia Covelli
DSDiana Sacchi
Diana Sacchi
SSSamantha Sarcognato
Samantha Sarcognato
NCNora Cazzagon
Nora Cazzagon
FGFederica Grillo
Federica Grillo
MGMaria Guido
Maria Guido
Autoimmune hepatitis (AIH) is a relatively rare non-resolving chronic liver disease, which mainly affects women. It is characterized by hypergammaglobulinemia, circulating autoantibodies, interface hepatitis on liver histology and a favourable response to immunosuppression. The putative mechanism for the development of autoimmune hepatitis is thought to be the interaction between genetic predisposition, environmental triggers and failure of the native immune system. AIH still remains a major diagnostic and therapeutic challenge, mainly because it is a very heterogeneous disease. Prompt and timely diagnosis is crucial since, if left untreated, AIH has a high mortality rate. Histological demonstration of hepatitis is required for the diagnosis of AIH and, therefore, liver biopsy is mandatory in the initial diagnostic work-up, before treatment. In this review, we summarize the histological features of AIH with the main aim of highlighting the most important clinical-pathological hallmarks useful in the routine diagnostic practice.